MedPath

Early Prostate cancer recurrence with PSMA PET positive unilateral pelvic lesion(s): is one-sided salvage extended lymph node dissection enough?

Not Applicable
Recruiting
Conditions
C61
Malignant neoplasm of prostate
Registration Number
DRKS00020130
Lead Sponsor
Martini-Klinik am UKE GmbH
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Male
Target Recruitment
397
Inclusion Criteria

• Patients in good general condition with life expectancy> 10 years
• Hormone-sensitive prostate cancer recurrence after radical prostatectomy (patients with status post salvage prostatectomy may be included; salvage radiotherapy for prostate fossa and / or pelvic lymph drainage after radical prostatectomy is not an exclusion criterion)
• Unilateral detection of = 3 PSMA PET positive lymph node metastases in the pelvis (up ot origin of the inferior mesenteric artery)
• PSA at the time of PSMA PET imaging <4 ng / ml

Exclusion Criteria

• Contraindication for surgery or bilateral salvage lymph node dissection
• Suspected prostate cancer recurrence in the prostate fossa (local recurrence) or extrapelvic metastasis on PSMA PET imaging
• Date of PSMA PET examination > 4 months prior to salvage lymph node dissection
• Hormone therapy within 6 months prior to study enrollment

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Rate of complete biochemical response (cBR: PSA <0.2ng / ml) 24 months after salvage lymph node dissection without adjuvant prostate cancer specific therapy
Secondary Outcome Measures
NameTimeMethod
• Rate of complete biochemical response (cBR: PSA <0.2ng / ml) 4 weeks, 3, 6 and 12 months after salvage lymph node dissection without adjuvant prostate cancer specific therapy<br>• Prostate cancer-specific therapy-free survival after salvage lymph node 3, 6, and 12 months after salvage lymph node dissection<br>
© Copyright 2025. All Rights Reserved by MedPath